We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+44.2%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.62B
AUM Growth
+$469M
Cap. Flow
-$157M
Cap. Flow %
-5.99%
Top 10 Hldgs %
40.11%
Holding
87
New
14
Increased
8
Reduced
51
Closed
6

Top Buys

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$147M
2
RNAM
Avidity Biosciences
RNAM
+$72.5M
3
ARCT icon
Arcturus Therapeutics
ARCT
+$18.5M
4
PLRX icon
Pliant Therapeutics
PLRX
+$16.2M
5
QURE icon
uniQure
QURE
+$11.5M

Top Sells

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$64.1M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$33.9M
3
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$31.5M
4
XLRN
Acceleron Pharma
XLRN
+$21.7M
5
IMVTU
Immunovant, Inc. Units
IMVTU
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 81.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBPH icon
76
Theravance Biopharma
TBPH
$877M
$2.1M 0.08%
100,000
– –
NERV icon
77
Minerva Neurosciences
NERV
$199M
$1.85M 0.07%
64,020
-11,968
-16% -$702K
XFOR icon
78
X4 Pharmaceuticals
XFOR
$460M
$1.76M 0.07%
10,966
-421
-4% -$115K
FATE icon
79
Fate Therapeutics
FATE
$326M
$1.72M 0.07%
50,000
-25,000
-33% -$745K
ORTX
80
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.54M 0.06%
25,665
– –
OTLKW
81
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$117K ﹤0.01%
416,666
– –
ASND icon
82
CALL
Ascendis Pharma A/S
ASND
$16.8B
– –
-350,000
Closed -$39.4M
NBIX icon
83
Neurocrine Biosciences
NBIX
$16.6B
– –
-25,000
Closed -$2.16M
MRTX
84
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-500,000
Closed -$38.4M
RETA
85
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-250,000
Closed -$36.1M
CNST
86
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-2,040,021
Closed -$64.1M
IMVTU
87
DELISTED
Immunovant, Inc. Units
IMVTU
– –
-1,078,380
Closed -$19.4M
1 2 3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q2 2020 Portfolio in Review

As of Q2 2020, Cormorant Asset Management held 87 positions worth $2.62B, up 22% from $2.15B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Cormorant Asset Management withdrew a net $157M in Q2 2020, closing 6 positions and reducing 51 holdings. Its most notable exit was Constellation Pharmaceuticals, Inc., an estimated $64.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 76% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Forma Therapeutics Holdings, Inc. Common Stock worth $153M.

  • Cormorant Asset Management's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 3,379,373 shares worth $153M.
  • Cormorant Asset Management added most to Arcturus Therapeutics in Q2 2020, an estimated $18.5M increase.
  • Cormorant Asset Management's biggest Q2 2020 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $33.9M.
  • Cormorant Asset Management fully exited Constellation Pharmaceuticals, Inc. in Q2 2020, selling an estimated $64.1M.
  • Cormorant Asset Management's ten largest holdings make up 40% of its $2.62B portfolio in Q2 2020.
  • Cormorant Asset Management opened 14 new positions and closed 6 in Q2 2020.
  • Cormorant Asset Management's portfolio value rose 22% quarter-over-quarter to $2.62B.

Based on Cormorant Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.